i mu no modulator 2014
DESCRIPTION
imunoTRANSCRIPT
![Page 1: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/1.jpg)
IMUNOMODULATORIta Armyanti/Farmakologi 2014
1. Int J Pharm Pharm Sci, Vol 4, Suppl 1, 20122. GG 12ed3. Farmakologi FK UI
28/04/23 imunomodulator/2013 1
![Page 2: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/2.jpg)
IMMUNOPHARMACOLOGY
• Basic role of immune system distinguish self and non self
• 2 major components of the immune system:– INNATE (natural or non specific)
Physical – skin, mucus membrane Biochemical – complement, lyzosyme Cellular – macrophages, neutrophils
– ADAPTIVE (aquired or specific) Antibodies – HUMORAL immunity T-lymphocyte – CELL MEDIATED immunity
28/04/23 imunomodulator/2013 2
![Page 3: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/3.jpg)
COMPLEMENTS in Innate Immunity:
1. C3a, C5a chemotaxis
2. C3b opsonization
3. C5b, C6, C7, C8, C9 MAC
28/04/23 imunomodulator/2013 3
![Page 4: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/4.jpg)
0psonized bacteria
28/04/23 imunomodulator/2013 4
Macrophage
APC
T lymphocyte
IL-2 IL-2
IFN-
Activated
MacrophageActivated
NK cells
Activated
Cytotoxic T cell
CELL-MEDIATED IMMUNITY
B lymphocyte
IL-4,IL-5
TH1
TH2
Memory B Cells
Plasma Cells:
-IgG - IgM
- IgA - IgD
HUMORAL IMMUNITY
IFN-
TNF-IFN-
![Page 5: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/5.jpg)
T-helper cells:1. TH1 subset
- IFN- , IL-2, TNF-
2. TH2 subset- IL-4, IL-5, IL-6, IL-10
28/04/23 imunomodulator/2013 5
IMMUNOPHARMACOLOGY
![Page 6: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/6.jpg)
HYPERSENSITIVITY
AUTOIMMUNITY
IMMUNODEFICIENCY
28/04/23 imunomodulator/2013 6
ABNORMAL IMMUNE RESPONSES:
![Page 7: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/7.jpg)
1. Inhibitor of lymphocyte gene expression : glucocorticoids
2. Inhibitors of lymphocyte signaling3. Cytotoxic agents4. Cytokine inhibitors5. Antibodies against specific immune cell
molecules6. Inhibitors of immune cell adhesion7. Tolerogens or inhibitors of immune cell
costimulation8. miscellaneous
28/04/23 imunomodulator/2013 7
IMMUNOsuppressants
![Page 8: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/8.jpg)
Inhibitor of lymphocyte gene expression : glucocorticoids
• MOA: – inhibit T-cell proliferation & T-cell dependent
immunity– Inhibit expression of genes encoding cytokines– Inhibit production of inflammatory mediators
• Affects cell-mediated immunity more than humoral immunity
28/04/23 imunomodulator/2013 8
![Page 9: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/9.jpg)
• Continuous administration:– ↑ fractional catabolic rate of IgG
• Indications:– Autoimmune disorders
- autoimmune hemolytic anemia, LE- ITP, Inflammatory Bowel Dse,, Hashimoto’s
–Modulate allergic reactions - asthma– Organ transplantation – rejection crisis
28/04/23 imunomodulator/2013 9
![Page 10: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/10.jpg)
• Immunosuppressive dose: 10-100 mg/day
• Adverse effects: GI bleeding adrenal suppression fluid retention diabetes proximal muscle wasting superinfections
28/04/23 imunomodulator/2013 10
![Page 11: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/11.jpg)
Inhibitors of lymphocyte signaling
1. Calcineurin inhibitors : cyclosporine, tacrolimus
2. mTOR inhibitors : sirolimus, everolimus
28/04/23 imunomodulator/2013 11
![Page 12: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/12.jpg)
• produced by the fungus species Beauveria nivea• Blocks T-cell activation• binds to cyclophillin inhibits calcineurin
activity inhibits gene transcription of IL-2, IL-3, IFN & other factors
• Most commonly used immunosuppresant for renal transplantation
• Indications: transplant rejection (kidney, liver, pancreas, cardiac) Autoimmune disorders (uveitis, RA, DM type1)
• Toxicities: nephrotoxicity, hyperglycemia, hyperlipidemia,
osteoporosis, ↑ hair growth, transient liver dysfunction
28/04/23 imunomodulator/2013 12
Cyclosporin
![Page 13: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/13.jpg)
Tacrolimus• Macrolide antibiotic produced by Streptomyces
tsukubaensis• Binds to an intracelluler protein FK506-binding
protein inhibits T-cell activation
• 10-100 times more potent than cyclosporine
• Pediatric Liver transplantion & kidney transplant
• Oral or IV : t½ = 9-12 hrs, 99% metabolized by CYP3A
• Toxicity: nephrotoxicity, neurotoxicity, hyperglycemia, GI
dysfunction
28/04/23 imunomodulator/2013 13
![Page 14: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/14.jpg)
• Binds also to immunophyllin blocks the response of T-cell to cytokines
• Potent inhibitor of B-cell proliferation & Ig production
• Indications:– Kidney & heart allografts– C syclosporin psoriasis & uveoretinitis
28/04/23 imunomodulator/2013 14
Sirolimus (rapamycin)
![Page 15: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/15.jpg)
CYTOTOXIC Agents:
1. Azathioprine2. Mycophenolate mofetil3. Leflunomide4. Cyclophosphamide
28/04/23 imunomodulator/2013 15
![Page 16: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/16.jpg)
• Metabolized to 6-mercaptopurines
• Inhibit purine synthesis interferes with nucleic acid metabolism inhibits cellular & humoral responses
• Highly teratogenic
• Well absorbed from GI tract
28/04/23 imunomodulator/2013 16
Azathioprine
![Page 17: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/17.jpg)
• Renal allograft, AGN, SLE(renal), RA, Crohn’s disease
• Prednisone-resistant antibody-mediated ITP
• Autoimmune hemolytic anemia
• Toxicities:– Bone marrow suppression– GI disturbances: N&V, diarrhea– Skin rashes, drug fever, hepatic dysfunction
28/04/23 imunomodulator/2013 17
Azathioprine
![Page 18: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/18.jpg)
• Inhibits a series of T & B lymphocyte responses
• Inhibit de novo pathway of purine synthesis
• Renal & heart transplantation
• Mizoribine – inhibitor nucleotide synthesis pathway; kidney transplants
• Brequinar Sodium – inhibitors de novo pathway of pyrimidine synthesi; cancer & organ transplantation
28/04/23 imunomodulator/2013 18
Mycophenolate Mofetil
![Page 19: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/19.jpg)
• Prodrug of an inhibitor of pyrimidine synthesis
• Inhibits lymphoid cells
• Orally active
• RA
• Toxicities: – Headache, nausea & diarrhea– Hepatic dysfunction, renal impairment
• Teratogenic28/04/23 imunomodulator/2013 19
Leflunomide
![Page 20: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/20.jpg)
• Most potent immunosuppressive drug
• Destroys proliferating lymphoid cells
• Autoimmune disorders: SLE
• Acquired factor XIII antibodies
• Bleeding syndromes
• Toxicities: – Pancytopenia, hemorrhagic cystitis
28/04/23 imunomodulator/2013 20
Cyclophosphamide
![Page 21: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/21.jpg)
• INFLIXIMAB – Chimeric IgG1 monoclonal antibody with human
region & murine regions– Suppress generation of cytokines– Crohn’s disease; RA
• ETANERCEPT – Chimeric protein with human regiom– Similar MOA with infliximab but shorter half-life– RA
28/04/23 imunomodulator/2013 21
Cytokine inhibitors : TNF- α inhibitors
![Page 22: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/22.jpg)
Antibodies as Immunosuppressive Agents
• Antilymphocytic antibody
• Immune Globulin IV
• Hyperimmune Immunoglobulins
• Monoclonal Antibodies
• Rho(D) Immune Globulin Micro-DosePrevention of hemolytic disease of the
newbornGiven to mother within 72 hrs after delivery of
an Rh-negative baby28/04/23 imunomodulator/2013 22
![Page 23: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/23.jpg)
1.Muromonab- CD3
2. Palivizumab
3. Rituxumab
4.Trastuzumab28/04/23 imunomodulator/2013 23
MONOCLONAL ANTIBODIES:
![Page 24: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/24.jpg)
• T-cell specific antibody IL2
• I : Renal transplantation, heart / renal
28/04/23 imunomodulator/2013 24
Muromonab-CD3
![Page 25: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/25.jpg)
• Palivizumab – RSV
• Rituximab – follicular B-cell non-hodgekins lymphma
• Trastuzumab – metastatic breast CA
28/04/23 imunomodulator/2013 25
IMMUNOPARMACOLOGY
![Page 26: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/26.jpg)
IMMUNOSTIMULANTS
LEVAMISOLE:
- antiparasitic agent - potentiate action of fluorouracil in adjuvant therapy of Dukes class C colorectal CA- other uses:
> hodgkin’s lymphoma> RA
28/04/23 imunomodulator/2013 26
![Page 27: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/27.jpg)
BCG (Bacille-Camille-Guarin):
- immunization against tuberculosis
- Adjuvant in intravesical therapy for SF bladder CA
28/04/23 imunomodulator/2013 27
![Page 28: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/28.jpg)
• Type 1: induced by viral inf.– IFN-alpha prod. by leukocytes– IFN-beta prod. by fibroblasts & epithelial cells
• Type 2: IFN-gamma produced by activated T-lymphocytes
• Indications: cancer• IFN- multiple sclerosis• IFN- chronic granulomatous disease
28/04/23 imunomodulator/2013 28
Interferons
![Page 29: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/29.jpg)
• Potent antimonocytic & antilymphocytic effect
• Inhibits T & B lymphocyte response
• Renal transplants; pancreas & heart transplants
28/04/23 imunomodulator/2013 29
15-Deoxyspergualin
![Page 30: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/30.jpg)
• Sedative drug
• Favors TH2 over TH1
• Suppress TNF-α production
• Antiangiogenesis action: teratogenicity & anticancer
• Indications– Erythema nodosum leprosum (skin
manifestations of SLE)– Lung transplantation
28/04/23 imunomodulator/2013 30
Thalidomide
![Page 31: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/31.jpg)
• Relapsing-remitting form of multiple sclerosis
• Subcutaneous injection
• Toxicities:– Transient post-injection reaction
28/04/23 imunomodulator/2013 31
Glatiramer
![Page 32: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/32.jpg)
IMMUNOMODULATORS• CYTOKINES
28/04/23 imunomodulator/2013 32
Interferon-alpha:
- hairy cell leukemia- chronic myelogenous leukemia- malignant melanoma- Kaposi’s sarcoma- anticancer renal cell CA, carcinoid syndrome, T cell leukemia
![Page 33: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/33.jpg)
RECOMBINANT CYTOKINES
Interferon-beta Relapsing type multiple sclerosis
Interferon-gamma Chronic granulomatous disease
Interleukin-2 Metastatic renal cell CA Malignant melanoma
TNF-alpha Malignant melanomaSoft tissue sarcoma of extremities
Interferons & IL-2 (+) effects in response to Hep B vaccine
GM-CSF Melanoma and Prostate cancer28/04/23 imunomodulator/2013 33
![Page 34: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/34.jpg)
IMMUNOMODULATORSHIV:
- Inosiplex- Diethylcarbamate (DTC)
DiGeorge Syndrome of T cell deficiency - give THYMOSIN
28/04/23 imunomodulator/2013 34
![Page 35: i Mu No Modulator 2014](https://reader034.vdocument.in/reader034/viewer/2022042905/577c83ad1a28abe054b5c0a0/html5/thumbnails/35.jpg)
postest
Pada kasus transplantasi organ, kortikosteroidpilihan yang dapat diberikan adalah ?Indikasi interferons?Monoklonal antibodi?Efek samping talidomide ?MoA levamisole?BCG?
28/04/23 imunomodulator/2013 35